Agilis Biotherapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 8

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $534M

Agilis Biotherapeutics General Information

Description

Developer of DNA based therapeutics designed to treat life-threatening or fatal rare diseases. The company's DNA based therapeutics uses the transformative approach based on delivering a corrected copy of a naturally occurring gene directly to targeted cells designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Kendall Square, 245 First Street
  • Suite 1800
  • Cambridge, MA 02142
  • United States
+1 (339)
Primary Industry
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • Kendall Square, 245 First Street
  • Suite 1800
  • Cambridge, MA 02142
  • United States
+1 (339)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Agilis Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 23-Aug-2018 $534M Completed Generating Revenue
3. Early Stage VC (Series B) 24-Feb-2017 Completed Generating Revenue
2. Early Stage VC (Series B) 25-Jan-2016 $5M Cancelled Startup
1. Early Stage VC (Series A) 24-Dec-2013 $8M $8M Completed Startup
To view Agilis Biotherapeutics’s complete valuation and funding history, request access »

Agilis Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Agilis Biotherapeutics’s complete cap table history, request access »

Agilis Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of DNA based therapeutics designed to treat life-threatening or fatal rare diseases. The company's DNA based t
Biotechnology
Cambridge, MA
8 As of 2016

Somerville, MA
 

Redwood City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Agilis Biotherapeutics Competitors (53)

One of Agilis Biotherapeutics’s 53 competitors is Genetix Biotherapeutics, a Private Equity-Backed company based in Somerville, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Adverum Biotechnologies Formerly VC-backed Redwood City, CA
Regenxbio Formerly VC-backed Rockville, MD
Prevail Therapeutics Formerly VC-backed New York, NY
ERS Genomics Corporate Backed or Acquired Dublin, Ireland
You’re viewing 5 of 53 competitors. Get the full list »

Agilis Biotherapeutics Patents

Agilis Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11998618-B2 Frataxin expression constructs Active 09-Nov-2016
US-20210177991-A1 Frataxin expression constructs Active 09-Nov-2016
US-20240000973-A1 Frataxin expression constructs Inactive 09-Nov-2016 A61K48/0058

Agilis Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Agilis Biotherapeutics Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioMatrix Partners Venture Capital Minority
Gold Bench Capital Venture Capital Minority
Sands Capital Growth/Expansion Minority
Third Security Venture Capital Minority
WhiteRock Capital Partners Investment Bank Minority
To view Agilis Biotherapeutics’s complete investors history, request access »

Agilis Biotherapeutics Investments (1)

Agilis Biotherapeutics’s most recent deal was a Joint Venture with Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution). The deal was made on 02-Aug-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) 02-Aug-2017 Joint Venture Drug Discovery
To view Agilis Biotherapeutics’s complete investments history, request access »

Agilis Biotherapeutics FAQs

  • When was Agilis Biotherapeutics founded?

    Agilis Biotherapeutics was founded in 2013.

  • Where is Agilis Biotherapeutics headquartered?

    Agilis Biotherapeutics is headquartered in Cambridge, MA.

  • What is the size of Agilis Biotherapeutics?

    Agilis Biotherapeutics has 8 total employees.

  • What industry is Agilis Biotherapeutics in?

    Agilis Biotherapeutics’s primary industry is Biotechnology.

  • Is Agilis Biotherapeutics a private or public company?

    Agilis Biotherapeutics is a Private company.

  • What is the current valuation of Agilis Biotherapeutics?

    The current valuation of Agilis Biotherapeutics is .

  • What is Agilis Biotherapeutics’s current revenue?

    The current revenue for Agilis Biotherapeutics is .

  • How much funding has Agilis Biotherapeutics raised over time?

    Agilis Biotherapeutics has raised $20.7M.

  • Who are Agilis Biotherapeutics’s investors?

    BioMatrix Partners, Gold Bench Capital, Sands Capital, Third Security, and WhiteRock Capital Partners have invested in Agilis Biotherapeutics.

  • Who are Agilis Biotherapeutics’s competitors?

    Genetix Biotherapeutics, Adverum Biotechnologies, Regenxbio, Prevail Therapeutics, and ERS Genomics are some of the 53 competitors of Agilis Biotherapeutics.

  • When was Agilis Biotherapeutics acquired?

    Agilis Biotherapeutics was acquired on 23-Aug-2018.

  • Who acquired Agilis Biotherapeutics?

    Agilis Biotherapeutics was acquired by PTC Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process